kirre like nephrin family adhesion molecule 3Genealiases: KIRRE · MRD4 · NEPH2 · PRO4502
Q-omics provides the consensus-scored KIRREL3 profile across patient tissues and cancer cell-line models. KIRREL3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIRREL3 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, KIRREL3 RNA expression shows 17,305 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where KIRREL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIRREL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIRREL3 survival associations across molecular data types. KIRREL3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIRREL3 RNA expression–survival associations across cancer types. High KIRREL3 expression shows unfavorable associations in ACC, KIRP, MESO, LUAD and UVM, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIRREL3 RNA expression.
This table summarizes KIRREL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KIRREL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIRREL3 shows lower tumor expression in BLCA, COAD, STAD, KICH, READ and PRAD. The BLCA box plot shows higher KIRREL3 RNA expression in normal versus tumor tissue (log2 FC = −0.536, t-test p < 0.001).
This table shows molecular features associated with KIRREL3 in patient tissues and cancer cell lines. In patient samples, KIRREL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIRREL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
